Moleculin Biotech, Inc. (MBRX) Form SCHEDULE 13D — Aug 25, 2026
Moleculin Biotech (MBRX) EVP and CFO Jonathan P. Foster filed a Schedule 13D disclosing beneficial ownership of 1,288,207 shares, equal to 6.30% of the company's 19,477,380 shares outstanding as of August 6, 2026. Foster acquired 293,333 shares plus Series I Common Warrants on 879,999 shares in the company's August 3, 2026 public offering, paying approximately $219,999.75 of personal funds at a combined price of $0.75 per one share plus three warrants, via a Form S-1 offering run by Roth Capital Partners.
Key figures
- Shares Outstanding
- 19477380
- Unit Price
- $0.75 per one share plus three Common Warrants
- Direct Shares
- 305673
- Warrant Expiration
- 2031-08-03
- Warrant Exercise Price
- 0.75
- Shares Outstanding As Of
- 2026-08-06
- Aggregate Purchase Price
- $219,999.75
- Ownership Blocker Change
- 4.99% increased to 9.99%, effective 2026-10-18
- Beneficially Owned Shares
- 1288207
- Warrant Underlying Shares
- 879999
- Warrant Anti Dilution Floor
- 0.21
- Beneficial Ownership Percent
- 6.30%
- Options And Warrants Exercisable Within60 Days
- 102535
AI analysis
Red flags4 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.